Thomas Strüngmann, along with his twin brother Andreas, is a notable German businessman and entrepreneur. They are best known for their early backing of the German biotech firm BioNTech, which partnered with Pfizer to develop a widely used Covid-19 vaccine.
Key highlights of their careers include:
1. Founding Hexal AG: In 1986, the Strüngmann brothers co-founded Hexal, a generic drug maker. Hexal became a significant player in the pharmaceutical industry and was sold to Novartis in 2005 for approximately $7 billion.
2. Investment through Santo Holding: The brothers invest in various biotech, pharmaceutical, life sciences, and healthcare companies through their investment firm, Santo Holding, based in Zug, Switzerland.
3. BioNTech Investment: Their early investment in BioNTech played a crucial role in the development of a COVID-19 vaccine in partnership with Pfizer, marking a significant achievement in the fight against the pandemic.
4. Neuroscience Research Center: In 2008, they established a neuroscience research center in Frankfurt, named after their father, Ernst Strüngmann, demonstrating their commitment to advancing scientific research.
Thomas Strüngmann had a contributions to the pharmaceutical and biotech industries have been influential, and his ventures continue to impact healthcare and life sciences globally.
